2017 Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Group Chronic Malignancies Working Party (CMWP) 1st listed author Auner HW Journal Haematologica.
2017 Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. Group Chronic Malignancies Working Party (CMWP) 1st listed author Sobh M Journal Haematologica.
2017 Haploidentical transplant in patients with myelodysplastic syndrome. Group Chronic Malignancies Working Party (CMWP) 1st listed author Robin M Journal Blood Adv.
2017 Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Group Chronic Malignancies Working Party (CMWP) 1st listed author Schmid C Journal Haematologica.
2017 Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. Group Chronic Malignancies Working Party (CMWP) 1st listed author Garderet L Journal Biol Blood Marrow Transplant.
2017 Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Group Chronic Malignancies Working Party (CMWP) 1st listed author van Gelder M Journal Bone Marrow Transplant.
2017 Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Group Chronic Malignancies Working Party (CMWP) 1st listed author Martino R Journal Bone Marrow Transplant.
2017 Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation. Group Chronic Malignancies Working Party (CMWP) 1st listed author Schetelig J Journal Bone Marrow Transplant.
2017 Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. Group Chronic Malignancies Working Party (CMWP) 1st listed author Scheid C Journal Bone Marrow Transplant.
2017 Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Group Chronic Malignancies Working Party (CMWP) 1st listed author de Witte T Journal Blood
2017 Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Group Chronic Malignancies Working Party (CMWP) 1st listed author Onida F Journal Br J Haematol.
2017 Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT. Group Chronic Malignancies Working Party (CMWP) 1st listed author van Gelder M Journal Clin Lymphoma Myeloma Leuk.